Feasability of high dose Melphalan (HDMel) and peripheral blood stem cell support for patients over 60 years with acute myeloid leukemia in first remission

MLA

Stoppa, Am, et al. Feasability of High Dose Melphalan (HDMel) and Peripheral Blood Stem Cell Support for Patients over 60 Years with Acute Myeloid Leukemia in First Remission. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..1cb3f2735f450502d10aa69d41ae5e78&authtype=sso&custid=ns315887. Accessed 27 Nov. 2024.

APA

Stoppa, A., Vey, N., Faucher, C., Bouabdallah, R., Costello, R., Coso, D., Aurran, T., Charbonnier, A., Schianno, J., Chabannon, C., Ladaique, P., Novakovitch, G., Sainty, D., Lafage, M., Didier Blaise, Gastaut, J., & Maraninchi, D. (n.d.). Feasability of high dose Melphalan (HDMel) and peripheral blood stem cell support for patients over 60 years with acute myeloid leukemia in first remission.

Chicago

Stoppa, Am, N. Vey, C. Faucher, R. Bouabdallah, R. Costello, D. Coso, T. Aurran, et al. 2024. “Feasability of High Dose Melphalan (HDMel) and Peripheral Blood Stem Cell Support for Patients over 60 Years with Acute Myeloid Leukemia in First Remission.” Accessed November 27. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..1cb3f2735f450502d10aa69d41ae5e78&authtype=sso&custid=ns315887.